The U.S. Food and Drug Administration issued a Complete Response Letter (CRL) to Aquestive Therapeutics on January 30 2026, a decision the company publicly disclosed on February 2 2026. The CRL concerns the company’s flagship product, Anaphylm, a sublingual epinephrine film designed to treat anaphylaxis without a needle.
The FDA’s letter cites deficiencies in a human‑factor validation study, specifically problems with pouch opening and film placement that could compromise safety during an emergency. Because the issues relate to how patients open the pouch and apply the film, the FDA cannot discuss labeling or post‑marketing commitments until the company resolves these concerns.
The CRL delays Anaphylm’s market entry and postpones the company’s projected revenue launch. It also threatens the timing of planned financing and debt refinancing that are contingent on FDA approval, potentially affecting the company’s capital structure and growth strategy.
In response, Aquestive plans a Type A meeting with the FDA to outline a remediation strategy and aims to resubmit the application in the third quarter of 2026. The company has already redesigned the pouch opening, updated instructions for use, revised labeling, and will conduct a new human‑factor validation study to address the FDA’s concerns.
Investors reacted strongly to the announcement, with the stock surging 35‑43 % on the day of the disclosure. Analysts attribute the positive reaction to the fact that the FDA’s deficiencies are limited to human‑factor issues rather than efficacy, safety, or manufacturing concerns, indicating that the product’s core clinical profile remains intact.
The delay gives competitors such as ARS Pharmaceuticals’ Neffy, a nasal spray approved in 2024, more time to capture market share. Aquestive continues to pursue international approvals, with submissions planned for Europe and Canada in the second half of 2026, and has received encouraging feedback from regulators abroad that no additional clinical trials are required.
Analysts now expect a roughly 12‑month delay, pushing Anaphylm’s launch into 2027. Management remains confident that the human‑factor issues are solvable and that the company can achieve rapid review once the deficiencies are addressed.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.